Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

NCT ID: NCT00979953

Last Updated: 2015-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 408 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-10-31
• Study Completion Date: 2010-06-30

Brief Summary

The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747 versus placebo in relieving pain in participants with osteoarthritis of the knee.

Conditions

Osteoarthritis of the Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ADL5859

One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days

Group Type: EXPERIMENTAL

ADL5859

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

ADL5747

One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days

Group Type: EXPERIMENTAL

ADL5747

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Oxycodone CR

One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4

One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14

Group Type: ACTIVE_COMPARATOR

Oxycodone CR

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Placebo

Four placebo capsules administered orally BID for 14 days

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

ADL5859

Intervention Type: DRUG

ADL5747

Intervention Type: DRUG

Oxycodone CR

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

OxyContin

Eligibility Criteria

Inclusion Criteria

• a man or woman between 18 and 75 years of age, inclusive
• for women of childbearing potential, be using an insertable, injectable, transdermal, or combination oral contraceptive deemed highly effective by the United States Food and Drug Administration from the first dose of study medication through the end of the study and have negative findings on pregnancy tests performed at screening and randomization (women who are surgically sterile [for example, hysterectomy, tubal ligation] or postmenopausal [if ≥55 years old, no menses for at least 2 years; if <55 years old, follicle-stimulating hormone concentrations within the postmenopausal range of >40 milli-international units per milliliter (mIU/mL) and 17 β-estradiol levels of <37 picograms per milliliter (pg/mL)] are also eligible to participate)
• for male participants, be surgically sterile or agree to use an appropriate method of contraception (that is, use a barrier method in conjunction with spermicide or have a sexual partner who is surgically sterile, postmenopausal, or using an insertable, injectable, transdermal, or combination oral contraceptive deemed highly effective by the United States Food and Drug Administration) from the first dose of study medication through the end of the study
• have a body weight between 45 and 150 kilograms (kg), inclusive
• have had pain in the index knee for at least the past 6 months
• meet the following criteria for osteoarthritis of the knee established by the American College of Rheumatology (radiographs must have been taken within the last year; if none is available, a radiograph must be taken and the diagnostic criteria must be confirmed before the participant is enrolled in the study): have index knee pain plus at least 1 moderate or definite osteophyte on radiographs. Must also have at least 1 of the following: be more than 50 years old, have morning stiffness for less than 30 minutes, or have crepitus on active motion
• have an average weekly pain score of at least 4.00 on the numeric pain rating scale (NPRS) for the index knee during the baseline week before randomization (to be eligible for randomization, participants must report their NPRS score via the interactive voice-response system (IVRS) for at least 4 of the 7 days immediately before randomization, with the first score being recorded on Day -6)
• if receiving nonselective or selective cyclooxygenase (COX) inhibitors, have a stable daily dose regimen for at least 4 weeks before screening; if receiving nonselective or selective COX inhibitors on an as needed basis, have discontinued use by Day -14; if receiving angiotensin-converting enzyme (ACE) inhibitors, have a stable dose regimen for at least 4 weeks before screening

Exclusion Criteria

• have undergone arthroscopy on the index knee within 6 months before study entry
• have other severe pain that, in the opinion of the investigator, may impair the assessment of the pain due to osteoarthritis
• have a history of hypersensitivity or intolerance to opioids (including tramadol and tapentadol)
• have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, hematologic, cardiovascular, metabolic, gastrointestinal, neurologic, psychiatric, or another condition that would preclude participation in the study or affect the outcome of the study
• have taken oral or intramuscular corticosteroids within 30 days before study entry (inhaled or topical corticosteroids are permitted)
• have received intra-articular injections of corticosteroids into the index joint within 12 weeks before screening
• have received intra-articular injections of hyaluronic acid into the index joint within 24 weeks before screening
• currently taking medications other than nonsteroidal anti-inflammatory drugs prescribed for chronic pain (such as duloxetine or pregabalin)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bruce Berger, MD

Role: STUDY_DIRECTOR

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Locations

Covance CRU, Inc

Daytona Beach, Florida, United States

Atlanta Knee and Shoulder Clinic, PC

Stockbridge, Georgia, United States

University Rheumatoloty Center for Clinical Research

Chicago, Illinois, United States

Clinical Investigation Specialists, Inc

Gurnee, Illinois, United States

Cresent Medical Research

Salisbury, North Carolina, United States

New Hanover Medical Research

Wilmington, North Carolina, United States

Columbus Clinical Research

Columbus, Ohio, United States

PSB Research

Mount Gilead, Ohio, United States

Bone Joint & Spine Surgeons, Inc

Toledo, Ohio, United States

Radient Research

Anderson, South Carolina, United States

Quality Research

San Antonio, Texas, United States

Countries

United States

Other Identifiers

44CL240

Identifier Type: -

Identifier Source: org_study_id